In recent years, it has become increasingly apparent that diffuse large B-cell lymphoma (DLBCL) is not a single pathologic entity. Widely available diagnostic techniques such as immunohistochemical staining and fluorescence in situ hybridization (FISH) have helped to subcategorize DLBCLs by their pathologic features and identify those associated with a lower probability of cure after standard first-line rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). This recognition has prompted increased use of diagnostic testing to identify patients with high-risk aggressive lymphoma, the results of which have, at times, led clinicians to offer such patients alternative first-line treatment regimens in hopes of increasing their likelihood of achieving cure. Here, we further explore this concept of molecular risk stratification among patients with DLBCL or high-grade B-cell lymphoma (HGBL), consider potential limitations to performing such stratification in current practice, and suggest how risk stratification may be more optimally implemented now and in the future.

中文翻译：

---

侵略性B细胞淋巴瘤的分子风险分层。

近年来，越来越明显的是弥漫性大B细胞淋巴瘤（DLBCL）不是单个病理实体。广泛可用的诊断技术（例如免疫组织化学染色和荧光原位杂交（FISH））已帮助按其病理学特征对DLBCL进行亚分类，并在标准一线利妥昔单抗联合环磷酰胺，阿霉素，长春新碱和泼尼松治疗后，发现与较低治愈率相关的那些（R-CHOP）。这种认识促使人们越来越多地使用诊断测试来鉴定患有高危侵袭性淋巴瘤的患者，其结果有时使临床医生为此类患者提供替代的一线治疗方案，以期增加他们获得治愈的可能性。这里，